In brief, the HSC gene therapy process for SCD involves harvesting bone marrow HSCs, selecting and genetically modifying the CD34+ cells, and ultimately reinfusing the engineered cells back into the patient (Figure 1). The gene discussed is CD34; the disease is Schnyder corneal dystrophy.